Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued on Tuesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of Ayala Pharmaceuticals stock opened at $0.03 on Tuesday. The stock has a market cap of $1.28 million, a PE ratio of 0.00 and a beta of 1.68. The business has a fifty day simple moving average of $0.03 and a 200-day simple moving average of $0.04. Ayala Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $0.78.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.